Bevacizumab (BVZ) as second-line treatment after sorafenib (SFB) progression in patients (pts) with advanced hepatocellular carcinoma (HCC).

Pazo-Cid, Roberto; Esquerdo, G.; Puértolas, Teresa; Calderero, V.; Gil, Iván Núñez; Lao, Juan; Millastre, E.; Alvarez-Alejandro, M.; Madani, Julia; Antón, A.

doi:10.1200/jco.2010.28.15_suppl.e14619

Cited by 7 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Combination therapy of bevacizumab and the mTOR inhibitor RAD001 for advanced or metastatic HCC is tolerated acceptably, and TTP in those patients on active therapy is comparable to sorafenib monotherapy [130]. In contrast, bevacizumab is active and well tolerated as a second-line treatment in advanced HCC patients resistant to first-line sorafenib therapy [131].…”

Section: Bevacizumabmentioning

confidence: 99%

Evolving Molecular Mechanism-Based Strategies for Control of Hepatocellular Carcinoma

Sato¹,

Mori

2011

CMC

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is a major cause of cancer mortality worldwide. Unresectable or metastatic HCC has a poor prognosis, and systemic cytotoxic chemotherapy has failed to show a substantial benefit for patients with HCC. However, there has been increasing interest in developing novel molecularly targeted agents in HCC due to the accumulation of knowledge of cell signaling and molecular carcinogenesis. Furthermore, some of these agents have proven to be efficacious in other traditionally challenging carcinomas, such as renal cell carcinoma. Recently, a phase III, randomized, placebo-controlled trial demonstrated that sorafenib, an oral multikinase inhibitor of the vascular endothelial growth factor receptor and Ras kinase, improves overall survival (OS) in patients with advanced HCC. This seminal study described the first agent to improve OS in HCC and began a new era of molecule-targeted cancer therapies. Currently, many novel molecularly targeted agents are under evaluation in clinical trials. In this review, we comprehensively summarize the molecular pathogenesis, targets, and signal transduction pathways involved in HCC. We also detail the current status of molecularly targeted agents that are under clinical development in advanced HCC, including the mechanisms of action of these agents.

show abstract

Section: Bevacizumabmentioning

confidence: 99%

Evolving Molecular Mechanism-Based Strategies for Control of Hepatocellular Carcinoma

Sato¹,

Mori

2011

CMC

View full text Add to dashboard Cite

show abstract

“…Bevacizumab has been studied as a potential agent in treating HCC alone or in combination with first line sorafenib. A phase II pilot study was conducted that assessed bevacizumab’s efficacy and tolerability in patients with HCC after disease progression on sorafenib ( 35 ). The study showed that at a 12-month median follow-up, the average time to symptomatic progression was 3.8 months, time to radiological progression was 3.9 months, and OS was 9.5 months.…”

Section: Anti-angiogenicsmentioning

confidence: 99%

Hepatocellular carcinoma, novel therapies on the horizon

Dika¹,

Makki²,

Abou‐Alfa³

2021

Chin Clin Oncol

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is the most common primary liver cancer and is associated with high mortality rate. Incidence remains high due to the persistent prevalence of viral hepatitis, alcoholic cirrhosis, and non-alcoholic fatty liver disease (NFLD). Despite screening efforts, the majority of patients present with advanced disease, add to the high risk of recurrence after curative surgery. Conventional chemotherapy did not alter the nature history of advanced and metastatic HCC. The discovery of multiple tyrosine kinase inhibitors (TKIs) led to the approval of sorafenib as first efficacious therapy. A new era in the treatment paradigm of HCC is evolving. Since the advent of sorafenib as an active treatment option for patients presenting with advanced or metastatic disease, several agents have been examined. This was linked with many failures, and success stories to celebrate. Herein, we describe the historical progress and current advances of systemic therapies post-sorafenib. Lenvatinib, regorafenib, cabozantinib, ramucirumab, pembrolizumab, and nivolumab, are all presently added and available therapeutic options in the advanced setting. The evaluation of novel treatment combinations including anti-angiogenic, TKIs plus checkpoint inhibitors, add to dual checkpoint inhibitors is evolving rapidly starting with the advent of the combination of atezolizumab plus bevacizumab. Combining local and systemic therapies is being actively investigated, as an option for locally advanced disease conventionally treated with locoregional approaches. The horizon remains promising and continues to evolve for HCC a disease long considered with unmet needs.

show abstract

Systemic Therapy for Hepatocellular Carcinoma: Future Directions

Palmer

Cramp

2011

Clinical Dilemmas in Primary Liver Cancer

View full text Add to dashboard Cite

Bevacizumab (BVZ) as second-line treatment after sorafenib (SFB) progression in patients (pts) with advanced hepatocellular carcinoma (HCC).

Cited by 7 publications

References 0 publications

Evolving Molecular Mechanism-Based Strategies for Control of Hepatocellular Carcinoma

Evolving Molecular Mechanism-Based Strategies for Control of Hepatocellular Carcinoma

Hepatocellular carcinoma, novel therapies on the horizon

Systemic Therapy for Hepatocellular Carcinoma: Future Directions

Contact Info

Product

Resources

About